Premium
P‐selectin glycoprotein ligand‐1 is required for the development of cutaneous vasculitis induced by immune complex deposition
Author(s) -
Yanaba Koichi,
Komura Kazuhiro,
Horikawa Mayuka,
Matsushita Yukiyo,
Takehara Kazuhiko,
Sato Shinichi
Publication year - 2004
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.1203650
Subject(s) - selectin , arthus reaction , immunology , immune system , immune complex , inflammation , p selectin , mast cell , cell adhesion molecule , infiltration (hvac) , tumor necrosis factor alpha , monoclonal antibody , chemistry , antibody , biology , platelet , materials science , platelet activation , composite material
Immune complex (IC)‐induced tissue injury is mediated by inflammatory cell infiltration that is highly regulated by various adhesion molecules. To assess the contribution of P‐selectin glycoprotein ligand‐1 (PSGL‐1) and selectins in the pathogenetic process, the cutaneous reverse‐passive Arthus reaction was examined in mice treated with monoclonal antibodies (mAb) to PSGL‐1 or P‐ and/or E‐selectin. Edema and hemorrhage were significantly reduced in mice treated with anti‐P‐selectin mAb compared with control mice while they were not inhibited in mice treated with anti‐E‐selectin mAb. It is remarkable that blocking PSGL‐1 by mAb resulted in significant, further reduction in edema and hemorrhage compared with blocking anti‐P‐ or anti‐E‐selectin. However, blockade of E‐ and P‐selectins exhibited more significant reduction relative to PSGL‐1 blockade. The inhibited edema and hemorrhage paralleled reduced infiltration of neutrophils and mast cells. Reduced infiltration of neutrophils and mast cells was observed in the peritoneal Arthus reaction and was associated with the decreased production of tumor necrosis factor α and interleukin‐6. The results of this study indicate that PSGL‐1 contributes to the Arthus reaction mainly as a ligand of P‐selectin and partly as a ligand of E‐ and/or L‐selectin by regulating neutrophil and mast‐cell recruitment and that PSGL‐1 would be a therapeutic target for human IC‐mediated diseases.